Citius Pharmaceuticals Inc (CTXR) Receives a Buy from H.C. Wainwright


Citius Pharmaceuticals Inc (CTXR) received a Buy rating and a $3 price target from H.C. Wainwright analyst Vernon Bernardino today. The company’s shares closed yesterday at $0.95, close to its 52-week low of $0.94.

Bernardino wrote:

“We assume coverage of Citius Pharmaceuticals (CTXR) with a Buy rating and 12-month price target of $3. We used a discounted cash flow (DCF) methodology based on projected 2020-2030 revenues from sales of Mino-Lok to arrive at our 12-month price target of $3 for CTXR shares (25% discount rate and 1% terminal growth rate). As the shares have not recovered from a dilutive financing conducted in August 2018, CTXR stock still trades substantially below their 52-week trading range. Thus, we think CTXR is a compelling Buy ahead of the 1Q19 readout for the Phase 3 Mino-Lok trial.”

According to TipRanks.com, Bernardino is ranked #4777 out of 5153 analysts.

Citius Pharmaceuticals Inc has an analyst consensus of Hold.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4 and a one-year low of $0.94. Currently, Citius Pharmaceuticals Inc has an average volume of 103.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on September 9, 2010 and is headquartered in Cranford, NJ.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts